Αποτελέσματα Αναζήτησης
25 Νοε 2019 · CapVest, which specializes in mid-market buyouts, has hired JPMorgan and Rothschild to find a new owner for the Paris-based firm which makes nuclear tracers used in diagnostic imaging ...
1 Ιαν 2021 · Information on valuation, funding, acquisitions, investors, and executives for Curium Pharma (Paris). Use the PitchBook Platform to explore the full profile.
6 Απρ 2017 · Speaking on behalf of CapVest, the owner of Curium, Kate Briant, CapVest Partner and Chairman of the Board said, “We are excited to launch this dynamic new brand in the marketplace. We believe the expertise, size and scale, and proven track record of the united companies will provide future growth opportunities in this attractive segment.”
Curium is a global leader in the field of nuclear medicine. The company's primary offerings include the development, manufacturing, and distribution of radiopharmaceutical products, which are used in the diagnosis and treatment of various diseases. Curium primarily serves the healthcare sector, with a particular focus on cancer diagnostics and ...
Owner. Director, Executive Human Resources, Management, Medical & Science. 3 emails found 1 phone number found. View contacts for Curium Pharma to access new leads and connect with decision-makers. View All Contacts. Details. Industries. Pharmaceutical. Headquarters Regions European Union (EU), Europe, Middle East, and Africa (EMEA)
9 Ιαν 2020 · January 9, 2020. CVC Capital Partners, Bain Capital, Clayton Dubilier & Rice, Nordic Capital and PAI Partners have submitted first-round bids to acquire Curium Pharma from CapVest in a deal that would value the company at $3 billion or more, according to Bloomberg.
Curium Pharma is the largest nuclear medicine company with more than a century of industry experience. Curium develops, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe.
